相关实验视频

Updated: Jun 10, 2025

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

西尔德纳菲尔作为桥梁疗法,用于早产新生儿吸入氧化的治疗

Harris Khawaja¹, Timothy A Sanders¹, Michael Schreiber¹

¹Department of Pediatrics (HK, TAS, MS, GB), University of Chicago Medicine Comer Children's Hospital, Chicago, IL.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

|October 16, 2024

概括

西尔德纳菲尔帮助大多数早产婴儿停止吸入氧化 (iNO) 治疗,防止反弹性肺高血压,没有副作用. 这项研究探讨了西尔代纳菲尔.

科学领域:

新生儿医学新生儿医学
儿童心脏病学儿童心脏病学
药理学药理学是指药理学的学科.

背景情况:

吸入的氧化 (iNO) 对于治疗新生儿持续性肺高血压至关重要.
突然停止iNO可以导致危险的反弹性肺高血压.
需要采取替代策略,以安全地断奶婴儿从iNO.

研究的目的:

评估西尔德纳菲尔在促进早产新生儿iNO断奶过程中的疗效.
评估西尔代纳菲尔在该人群中用于iNO停药时的安全性.

主要方法:

在2017-2021年期间接受iNO和西尔代纳菲尔的早产新生儿 (妊娠年龄<34周) 的回顾性图表审查.
纳入标准:接受iNO,开始使用西尔代纳菲尔用于iNO断奶,没有重大先天性异常.
排除标准:先天性心脏病,先天性隔膜.

主要成果:

确定了7名新生儿 (GA 22 5/7至31 0/7周),他们之前曾尝试过iNO断奶,但未能成功.
西尔德纳菲尔剂量:0.125 mg/kg IV q8h 或 0.25 mg/kg 肠道 q8h.
在开始使用西德纳菲尔后的48小时内 (4名婴儿),5天 (1名婴儿) 或10天 (1名婴儿) 中断iNO.
一个婴儿经历了断奶失败;没有报告过低血压或死亡等不良事件.

结论:

在大多数评估过早的新生儿中,西尔德纳菲尔有效地促进了iNO的断奶.
在这个队列中,使用西尔德纳菲尔用于iNO断奶与有利的安全性相关.
西尔德纳菲尔是一种可行的选择,用于管理易受伤害的早产婴儿中iNO的中止.

关键词:

吸入的氧化氧化物这是新生儿新生儿.持续的肺高血压持续的肺高血压固酶5型的使用方法过早出生的新生儿时间过早的早产.这种药物是西尔代纳菲尔.

更多相关视频

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Published on: October 19, 2013

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Nitric Oxide Signaling Pathway

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Drug Delivery: Enteral Route

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...